default author photo

Gerard M. Bos

Maastricht University, Medical Center, Department of Hematology

Netherlands

SCHOLARLY PAPERS

3

DOWNLOADS

262

TOTAL CITATIONS

5

Scholarly Papers (3)

1.

Health-Related Quality of Life in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients Treated with Either Thalidomide or Lenalidomide-Based Regimen Until Progression (HOVON-87/NMSG18 Study): A Prospective, Open-Label, Multicenter, Randomized, Phase 3 Study

Number of pages: 89 Posted: 25 Feb 2019
Odense University Hospital - Quality of Life Research Center, VU University Amsterdam, VU University Amsterdam, Erasmus University Rotterdam (EUR) - Clinical Trial Center, South Elvsborg Hospital, University of Copenhagen - Rigshospitalet, Maastricht University, Medical Center, Department of Hematology, Albert Schweitzer Hospital - Department of Internal Medicine, Erasmus University Rotterdam (EUR) - Cancer Institute, Lund University - Skane University Hospital, Martini Ziekenhuis, Tergooi Hospital, Isala Zwolle, Vejle Hospital, Meander Medical Center - Department of Hematology, Forde Central Hospital, Northwest Clinics, Maasstad Hospital, Jeroen Bosch Hospital - Department of Hematology, University of Stavanger - Stavanger University Hospital, Zaans Medisch Centrum, University of Copenhagen - Rigshospitalet, VU University Amsterdam - Department of Hematology, Erasmus University Rotterdam (EUR) - Department of Hematology, Norwegian University of Science and Technology (NTNU), Odense University Hospital and VU University Amsterdam - Department of Hematology
Downloads 109 (645,052)

Abstract:

Loading...

Health-Related Quality of Life, Multiple Myeloma, Clinical Trial

2.

Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma

Number of pages: 147 Posted: 27 Jan 2020
University of Bologna - Seràgnoli Institute of Hematology, University of Turin, Ankara University, University of Bologna - Seràgnoli Institute of Hematology, Sapienza University of Rome, National and Kapodistrian University of Athens, University of Bologna - Seràgnoli Institute of Hematology, Erasmus University Rotterdam (EUR) - Clinical Trial Center, University of Turin, Erasmus University Rotterdam (EUR) - Erasmus Medical Center (MC), University of Bologna - Seràgnoli Institute of Hematology, University of Catania, Università degli Studi di Udine, Fondazione IRCCS Istituto Nazionale dei Tumori - Division of Hematology and Bone Marrow Transplantation, Papa Giovanni XXIII Hospital, Charles University in Prague, Azienda Unità Sanitaria Locale (AUSL) - IRCCS di Reggio Emilia, Lund University - Skane University Hospital, ASST-Spedali Civili of Brescia - Radiation Oncology Department, University Hospital Brno, Haga Hospital - Department of Hematology, Azienda Ospedaliera S.Croce-Carle, Radboud University Nijmegen - Department of Hematology, Ospedale Santa Maria della Misericordia, Ospedali Riuniti di Ancona, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, University of Padua, Università degli Studi di Perugia, Aarhus University - Aarhus University Hospital, VU University Amsterdam - Department of Hematology, University of Turin, Ospedale dell'Angelo, Città Della Salute e della Scienza, Albert Schweitzer Hospital - Department of Internal Medicine, Maastricht University, Medical Center, Department of Hematology, Wilhelminen Cancer Research Institute, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Ospedale Policlinico San Martino, Presidio Ospedaliero dello Spirito Santo, ZNA Stuivenberg, Amphia Hospital, University of Ostrava, Elisabeth-Tweesteden Hospital, Leiden University, Medical Center (LUMC), Department of Hematology, UOSD Ematologia ASL Roma, Cantonal Hospital of St. Gallen, Università degli Studi di Bari “Aldo Moro” (UNIBA), Norwegian University of Science and Technology (NTNU), University of Copenhagen - Rigshospitalet, South Elvsborg Hospital, Isala Kliniek, Utrecht University, University Medical Center, Cancer Center, Department of Hematology, Canisius-Wilhelmina Ziekenhuis, Grande Ospedale Metropolitano Niguarda, Ospedale San Francesco, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Monash University, University of Turin and Erasmus University Rotterdam (EUR) - Department of Hematology
Downloads 91 (736,406)
Citation 1

Abstract:

Loading...

multiple myeloma; autologous stem-cell transplantation; consolidation therapy; double autotransplantation

3.

Improved Survival with Thalidomide Before and after Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: Long-Term Results from the HOVON-50 Study

Number of pages: 102 Posted: 27 Jul 2018
VU University Amsterdam - Department of Hematology, Erasmus University Rotterdam (EUR) - Clinical Trial Center, Utrecht University, University Medical Center, Cancer Center, Department of Hematology, University of Groningen - Department of Hematology and Oncology, Radboud University Nijmegen - Department of Hematology, University of Amsterdam, Academic Medical Center, Department of Hematology, Leiden University, Medical Center (LUMC), Department of Hematology, Haga Hospital - Department of Hematology, Medisch Spectrum Twente - Department of Hematology, St. Antonius Ziekenhuis - Department of Hematology, Meander Medical Center - Department of Hematology, KU Leuven, Faculty of Medicine, Department of Hematology, Albert Schweitzer Hospital - Department of Internal Medicine, Maastricht University, Medical Center, Department of Hematology, Zuyderland Medical Center - Department of Hematology, Jeroen Bosch Hospital - Department of Hematology, Isala Zwolle - Department of Hematology, Medical Center Leeuwarden - Department of Hematology, VU University Amsterdam - Department of Hematology, Erasmus University Rotterdam (EUR) - Department of Hematology and VU University Amsterdam - Department of Hematology
Downloads 62 (951,658)
Citation 4

Abstract:

Loading...

multiple myeloma, randomized phase 3, thalidomide, newly diagnosed, autologous stem cell transplantation